Day: April 22, 2019
Fascinating! Group Visits May Outperform (Already Positive) Individual Outcomes at Cleveland Clinic Center for Functional Medicine
Is it possible that group visits can outperform individual visits in patient reported outcomes? The audience for an energetic panel discussion that touched on group visits at the February 2019 Integrative Healthcare Symposium heard an intriguing – though yet premature – data point. Panelist Mark Hyman MD noted that theRead
Four Articles: Cannabis and Cannabinoid Use in Palliative Care, Open Access until May 6, 2019
Patients are aware that medical cannabis and cannabinoid derivatives are available to treat pain and symptoms. However, the medical literature to guide palliative medicine physicians in recommending cannabis and cannabinoid use is not yet well developed. The Journal of Palliative Care, David Casarett, MD, Guest Editor and Chief of Palliative CareRead
Interaction of Neurotransmitters and Neurochemicals with Lymphocytes, including the Endocannabinoid System
Neurotransmitters and neurochemicals can act on lymphocytes by binding to receptors expressed by lymphocytes. This review describes lymphocyte expression of receptors for a selection of neurotransmitters and neurochemicals, the anatomical locations where lymphocytes can interact with neurotransmitters, and the effects of the neurotransmitters on lymphocyte function. Implications for health andRead
One Third of Cancer Patients Use Complementary Medicine, But Many Don’t Tell Their Doctors
With a cancer diagnosis, many people begin to seek complimentary forms of medicine to go with conventional treatments. A new study shows that one-third of people with a cancer diagnosis use complementary care options, such as meditation, yoga, acupuncture, herbal medicine, and supplements. The problem is that of these oneRead
Safety and Efficacy of Medical Cannabis in Elderly Patients: A Retrospective Review in a Neurological Outpatient Setting
As more states legalize medical cannabis, clinicians are seeking more information on how it may affect elderly populations for chronic conditions associated with aging. In this study, published in the journal Neurology, researchers evaluated medical cannabis’ (MC) efficacy and adverse effects (AE) in patients 75 years of age or older.Read
